Posters and Presentations

DDW 2026: Novel Oral Inhibitors of 15-PGDH Improve Disease Outcomes in DSS Mouse Models of Colitis
ICFSR 2026: Bridging Preclinical Efficacy with Phase 1 Target Engagement of MF-300, an Investigational First-in-Class Oral Agent for Sarcopenia
ICFSR 2026: Phase 1 Clinical Evaluation of MF-300 in Older Adults: An Investigational, First-In-Class Oral, Small Molecule in Development for Sarcopenia
GSA 2025: Phase 1 Evaluation of MF-300: An Investigational First-in-Class Oral Candidate for Sarcopenia
ICFSR 2025: MF-300 (15-PGDH Enzyme Inhibitor) Accelerates Recovery of Muscle Force in a Mouse Model of Nerve Injury
ICFSR 2025: MF-300 (15-PGDH Enzyme Inhibitor) Reverses Age-Related Muscle Weakness in Mice by Restoring Muscle Quality
GSA 2024: MF-300 (15-PGDH Enzyme Inhibitor) Reverses Age-Related Muscle Weakness in Mice by Restoring Muscle Quality
CureSMA 2023: Efficacy of MF 300 in Preclinical Models of Spinal Muscular Atrophy

Publications

Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength
Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength
Regeneration of neuromuscular synapses after acute and chronic denervation by inhibiting the gerozyme 15-prostaglandin dehydrogenase

©2026 Epirium Bio